Biophytis

    OverviewSuggest Edit

    Biophytis SA, formerly Institut Biophytis Sas is a France-based company engaged in the healthcare industry. The Company is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and age-related muscular degeneration (Armd). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
    TypePublic
    Founded2006
    HQRomainville, FR
    Websitebiophytis.com

    Latest Updates

    Employees (est.) (Feb 2019)19(+90%)

    Biophytis Office Locations

    Biophytis has an office in Romainville
    Romainville, FR (HQ)
    102, avenue Gaston Roussel
    Show all (1)

    Biophytis Online and Social Media Presence

    Embed Graph

    Biophytis News and Updates

    Biophytis Announces Results of 2019 Annual General Meeting of Shareholders

    PARIS and CAMBRIDGE, Mass., June 28, 2019 (GLOBE NEWSWIRE) -- Biophytis S.A. (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for age-related diseases, today announces the approval of all resolutions submitted to shareholders during …

    Biophytis Expands Daniel Schneiderman’s Role to Group Chief Financial Officer

    PARIS and CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for age-related diseases, today announced that Daniel Schneiderman, the Company’s Chief Financial Officer bas…

    Biophytis Announces Publication of its 2018 Annual Report

    PARIS and CAMBRIDGE, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for age-related diseases, today announced the publication of its 2018 Annual Report (Document de référence), w…

    Biophytis Files Registration Statement for Proposed Initial Public Offering in the United States

    PARIS and CAMBRIDGE, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for age-related diseases, today announced that it has publicly filed a registration statement with the U.S. Secur…

    Biophytis Reports Annual 2018 Financial Results and Provides Operational Update

    PARIS, France, March 12, 2019 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of novel treatments for age-related diseases, today announced annual 2018 financial results and provided an operational update. The Comp…

    Biophytis Announces Three Oral and One Poster Presentations at the 2019 International Conference on Frailty and Sarcopenia Research

    ICFSR 2019 will take place Feb. 20-22, 2019 in Miami Beach, FL ICFSR 2019 will take place Feb. 20-22, 2019 in Miami Beach, FL

    Biophytis Blogs

    AUGUST 23, 2019

    Biophytis has signed €24m bond funding from Negma to continue the development of its drug candidates to treat neuromuscular diseases. Read the Press Release

    AUGUST 8, 2019

    Shareholders Aprove All Resolutions of the Extraordinary General Meeting held on August 8, 2019. Read the Press Release

    JULY 25, 2019

    Biophytis Withdraws Registration Statement for Global Offering. Read the Press Release

    JULY 12, 2019

    Biophytis Announces Filing of Amendment to Registration Statement for Global Offering. Read the Press Release

    JULY 8, 2019

    Biophytis Announces the Launch of its Public Offering on Nasdaq. Read the Press Release

    june 26, 2019

    Biophytis Announces it Presented One Oral and One Poster Presentation at the MaculART meeting in Paris, France. Read the press release

    Biophytis Frequently Asked Questions

    • When was Biophytis founded?

      Biophytis was founded in 2006.

    • How many employees does Biophytis have?

      Biophytis has 19 employees.

    • Who are Biophytis competitors?

      Competitors of Biophytis include CTD Holdings, Enanta Pharmaceuticals and Endologix.

    • Where is Biophytis headquarters?

      Biophytis headquarters is located at 102, avenue Gaston Roussel, Romainville.

    • Where are Biophytis offices?

      Biophytis has an office in Romainville.

    • How many offices does Biophytis have?

      Biophytis has 1 office.